FindTrial
Sign In

Effecten van aspirine op de plaatjesfunctie bij gezonde vrijwillige proefpersonen.

Effecten van aspirine op de plaatjesfunctie bij gezonde vrijwillige proefpersonen.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-004354-90-NL
Enrollment
Unknown
Registered
2007-08-09
Start date
2007-10-03
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin resistance

Interventions

Trade Name: ascal cardio Product Name: carbasalate calium Pharmaceutical Form: Powder and solvent for oral solution CAS Number: 0005749-67-7 Other descriptive name: carbasalate calcium Concentration u

Sponsors

academisch ziekenhuis Maastricht
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age: 18-55 year non-smoker not pregnant BMI=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: no contra-indications for the use of carbasalate calcium: no history of gastric bleeding no asthma no known allergy for aspirin no bleeding disorders no liver or renal failure

Design outcomes

Primary

MeasureTime frame
Main Objective: The effects of aspirin on the platelet function of healty volunteers, measured by tromboxane B2, optic aggregation and platelet function analyser (PFA-100). The effects of aspirin on the platelet function of patients with possible aspirin resistance, measured by tromboxane B2, optic aggregation and platelet function analyser (PFA-100).;Secondary Objective: ;Primary end point(s): tromboxane B2 excretion (ng/mmol) optical aggregometry (%) PFA closure time (s)—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026